Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Pharma company Mercaptor has announced its new ‘breakthrough’ technology at J.P. Morgan HealthCare Conference which it says could transform Alzheimer's, TBI, and epilepsy treatment.
A significantly greater improvement in people with depression was achieved after they were given ALT-300, an adjunctive treatment, during a phase 2a study.
Researchers at the UK Dementia Research Institute have developed a new form of deep brain stimulation that does not require surgery and could provide an alternative treatment option for debilitating brain diseases such as Alzheimer’s.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
The Bill and Melinda Gates Foundation grant, awarded to data management platform Flywheel, will support pediatric brain development in impoverished areas.
A leader from the neurobiomarker platform provider tells how use of ML and other advanced analytical tools can help make better use of complex information.
The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.
The trials, funded by the American Heart Association, will harness the company’s Verisense wearable sensor platform to examine brain-heart health links.
Aluminium adjuvants should not be used in trial placebos according to UK scientists who say the differing physical and biological properties of alum salt forms makes some safer than others.
A collaboration involving academia and industry is to develop new ways of delivering antibodies to the brain using molecular envelop technology developed by Nanomerics, a UCL spin-out company.
A drug delivery technology that ‘shuttles’ molecules across the blood-brain-barrier could have major implications in developing drugs for disorders such as Alzheimer's and Parkinson’s disease, Roche says.
Non-profit epilepsy research sponsor, Epilepsy Therapy Project (ETP), has announced it is to invest in central nervous system (CNS) drug delivery specialist, ICVrx, to support the development of novel drug tech designed to tackle refractory epilepsy.
Pharma giant Eli Lilly and medical device maker Medtronic are to collaborate on the research and development of an implantable drug delivery system for the treatment of Parkinson’s disease.
Genzyme is evaluating to-BBB’s G-Technology as part of a research collaboration aimed at developing treatments capable of crossing the blood-brain barrier (BBB).
AngioChem has posted findings that its lead candidate using its propriety technology for crossing the blood-brain barrier (BBB) is safe and well tolerated.
A nanoparticle-based delivery system is being developed in the UK
as a potential means of bypassing the blood brain barrier and
improve the treatment of central nervous system diseases such as
brain cancer.
A novel technology set to overcome the challenges of the blood
brain barrier is being developed in a bid to open the gates to
previously unusable compounds for the treatment of central nervous
system (CNS) disorders.
Researchers have developed a new way to deliver drugs into the
brains of mice, which could herald a new dawn for the sufferers of
brain diseases such as Alzheimer's.
A start-up company has given new hope for patients with brain
tumour by developing a new medical device that it claims is the
first ultrasound-based system to allow drug delivery to the brain.
Researchers believe that new treatments or ways to diagnose memory
problems will get a boost from a substantial grant that aims to
create a brain-scanning method to test drug treatments, which
investigates how brain cells age, and...
Efforts to improve the efficacy of cancer therapy by blocking
cellular mechanisms that underlie resistance to cytotoxic drugs
have promised much but delivered little to date. Now, a team of
researchers in the US believe they have...
New research in the US, focusing on the pharmacological aspects of
smoking marijuana, are closer to understanding how the drugs active
ingredients exert its effects, paving the way for drugs that
selectively bind and block subtypes...
Researchers have developed the first tool to identify and study
individual neurons activated in a living animal, ultimately leading
to the development of targeted drugs that directly affect neurons
involved in neurological diseases...
